Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015288 · ClinicalTrials.gov registry record · Phase 1

Buprenorphine and Naloxone Combination Study - 10

A Phase 1 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00015288 is a Phase 1 study of Opioid-Related Disorders and Heroin Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015288, a Phase 1 study of Opioid-Related Disorders and Heroin Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

Interventions

  • DRUG Buprenorphine/naloxone

Study Locations (1)

New York

  • New York MDRU - New York

Trial Details

FieldValue
Start Date 1996-11
Phase Phase 1

What the Registry Record Tells You About NCT00015288

The ClinicalTrials.gov registry entry for NCT00015288 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.

NCT00015288 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00015288 about?

NCT00015288 is a clinical study titled "Buprenorphine and Naloxone Combination Study - 10". The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

What is the current status of trial NCT00015288?

This trial is currently completed. It is a Phase 1 study. The study started on 1996-11.

What conditions does trial NCT00015288 study?

This clinical trial studies the following conditions: Opioid-Related Disorders, Heroin Dependence.

What interventions are being tested in trial NCT00015288?

The interventions under investigation include: Buprenorphine/naloxone (DRUG).

Who is sponsoring clinical trial NCT00015288?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00015288 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.